Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
212 studies found for:    "essential thrombocythemia"
Show Display Options
RSS Create an RSS feed from your search for:
"essential thrombocythemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Anagrelide Retard in Essential Thrombocythemia
Condition: Essential Thrombocythemia
Interventions: Drug: Anagrelide retard;   Drug: Thromboreductin
2 Completed
Has Results
French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
Condition: Essential Thrombocythemia
Intervention:
3 Completed Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
Condition: Essential Thrombocythaemia
Interventions: Drug: Anagrelide;   Drug: Hydroxyurea
4 Completed
Has Results
The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)
Condition: Essential Thrombocythaemia
Intervention: Drug: anagrelide hydrochloride
5 Completed Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia
Condition: Essential Thrombocythaemia
Interventions: Drug: Anagrelide retard;   Drug: Placebo
6 Completed Pediatric Disease Registry in Essential Thrombocythaemia (ET)
Condition: Essential Thrombocythemia (ET)
Intervention:
7 Completed
Has Results
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
Condition: Essential Thrombocythemia (ET)
Intervention: Drug: SPD422 (anagrelide hydrochloride)
8 Not yet recruiting Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
Conditions: MPN;   Essential Thrombocythemia
Interventions: Other: Aspirin therapy interruption;   Other: Usual treatment by aspirin 100 mg/d in the active comparator arm;   Other: No interruption of aspirin in the Observational arm;   Drug: Hydroxyurea treatment (HU)
9 Not yet recruiting Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
Conditions: Myelofibrosis;   Essential Thrombocythemia
Intervention:
10 Unknown  A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: HDAC inhibitor (MK-0683)
11 Completed Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
Conditions: Essential Thrombocythemia;   Polycythemia Vera
Intervention: Drug: Imetelstat
12 Terminated Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Momelotinib
13 Completed Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Essential Thrombocythemia
Intervention: Drug: LY573636-sodium
14 Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
15 Active, not recruiting
Has Results
Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Ruxolitinib
16 Recruiting Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Aspirin
17 Recruiting Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Interventions: Drug: RG7388;   Drug: Pegasys
18 Recruiting The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
Conditions: Polycythemia Vera (PV);   Essential Thrombocythemia (ET)
Interventions: Drug: Ruxolitinib;   Drug: BAT
19 Not yet recruiting The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Condition: Essential Thrombocythemia
Interventions: Drug: Anagrelide;   Drug: Ruxolitinib (JAKAVI®);   Drug: IFNα/ PegIFNα
20 Completed
Has Results
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Condition: Essential Thrombocythaemia
Intervention: Drug: Anagrelide hydrochloride

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.